Hydroxychloroquine - Dr Zelenko Protocol for COVID-19
The original Zelenko protocol consists of zinc, low-dose hydroxychloroquine and azithromycin (Zithromax). Based on rapidly emerging clinical trials evidence of ivermectin, an anti-parasitic medicine, has highly potent real-world, anti-viral and anti-inflammatory properties against COVID-19 virus, Dr Zelenko has also included ivermectin as part of his prevention and treatment protocols.
Zelenko COVID-19 Prophylaxis Protocol
Low Risk Patients
Young healthy people do not need prophylaxis against COVID-19. In young and healthy people, this infection causes mild cold-like symptoms. It is advantageous for these patients to be exposed to Covid-19, build up their antibodies and have their immune system clear the virus. This will facilitate the development of herd immunity and help prevent future Covid-19 pandemics. However, if these patients desire prophylaxis against Covid-19, then they should take the protocol noted below.
Moderate Risk Patients
Patients from this category are healthy but have high potential viral-load exposure. This group includes medical personnel, caregivers of high-risk patients, people who use public transportation, first responders and other essential personnel who are crucial to the continued functioning of society. These patients should be encouraged to take prophylaxis against Covid-19 in accordance with the protocol noted below.
High Risk Patients
Patients are considered high risk if they are over the age of 45, or if they are younger than 45 but they have comorbidities, that is, they have other health conditions that put them at risk. These patients have between a 5 to 10% mortality rate if they are infected with Covid-19. These patients should be strongly encouraged to take prophylaxis against Covid-19 in accordance with the protocol noted below.
Elemental Zinc 25mg 1 time a day (PubMed) (Amazon)
Vitamin D3 5000 iu 1 time a day (vdnmeta.com) (Amazon)
Vitamin C 250 - 500 mg 1 time a day (PubMed) (Amazon)
Quercetin 250 mg 1 time a day until a safe and efficacious vaccine becomes available (J. Agric. Food Chem. 2014) (Amazon)
If Quercetin is unavailable, then use Epigallocatechin-gallate (EGCG) 200mg 1 time a day (J. Agric. Food Chem. 2014)
Hydroxychloroquine (HCQ) 200mg once a day for 5 days, then HCQ 200-400mg one time a week (ScienceDirect)
Vitamin C 1000mg once a day (Amazon)
Zinc 25-50mg/day (Amazon)
Ivermectin 0.2 mg/kg — one dose on day 1 and day 3, then take one dose weekly (ivmmeta.com).
Vitamin D3 5000 IU/day or 50000 IU once a week
Vitamin C 1000mg once a day
Zelenko Protocol - Treatment Plan for Patients with COVID-19 symptoms
Fundamental Principles (Dr Zelenko Protocol When to Start)
Patient CategoriesLow risk patient - Younger than 45, no co-morbidities, and clinically stable
High risk patient - Older than 45, younger than 45 with co-morbidities, or clinically unstable
Low risk patients - over the counter options:
2.2. Epigallocatechin-gallate (EGCG) 400mg 1 time a day for 7 days (J. Agric. Food Chem. 2014)
4. Vitamin D3 5000iu 1 time a day for 7 days (Amazon)
Moderate / High risk patients
Hydroxychloroquine (HCQ) 200mg 2 times a day for 5-7 days (ScienceDirect)
Ivermectin 0.4-0.5mg/kg/day for 5-7 days (ivmmeta.com).
Either or both HCQ and IVM can be used, and if one only, the second agent may be added after about 2 days of treatment if obvious recovery has not yet been observed etc.
If HCQ is not available, Quercetin 500mg 3 times a day for 7 days OR
EGCG 400mg 2 times a day for 7 days
In combination with the above (AND):
1. Elemental Zinc 50 - 100 mg 1 time a day for 7 days (Amazon)
2. Hydroxychloroquine (HCQ) 200mg 2 times a day for 7 days
3. Azithromycin 500mg 1 time a day for 5 days OR Doxycycline 100mg 2 times a day for 7 days
4. Vitamin C 1000 mg 1 time a day for 7 days (Amazon)
5. Vitamin D3 10,000 IU 1 time a day for 7 days (Amazon)
About Dr Vladimir ZelenkoHe graduated with a B.A. degree with high honors in Chemistry from Hofstra University. After receiving an academic scholarship to attend S.U.N.Y. at Buffalo School of Medicine, he earned his M.D. degree in May 2000. Dr. Zelenko completed his family medicine residency at South Nassau Communities Hospital in Oceanside, N.Y. in May 2004. Since then, Dr. Zelenko has practiced family medicine in New York’s Hudson Valley. He has been described by his patients as like a family member to thousands of families, and is a medical adviser to the volunteer ambulance corps in Kiryas Joel, New York.
When asked about studies that seemed to discredit the efficacy of HCQ in treating the Chinese coronavirus, Zelenko explained “You don’t fire a gun without a bullet in it and then say the gun doesn’t work when you don’t kill the target. The studies that were done on HCQ did not include the use of Zinc. HCQ is what opens the cell and enables Zinc to attack the virus. One is not effective without the other, or without a suitable substitute for HCQ. The studies were designed to fail.”
Dr. Zelenko says that both prophylaxis measures and actual case treatments need to be customized to the individual. As a general rule, he says, those people who are in the higher risk groups, both by age and by other pre-existing conditions, require more aggressive actions on both the preventative and diagnostic side.
“This virus remains relatively stable inside the host for about the first five days,” Zelenko says. “After that it starts to multiply rapidly. It also starts to migrate from sinus to lungs and cardio areas where involvement becomes more severe and treatment becomes more difficult. The key is early intervention.” Zelenko again mentioned his 84% success rate in high-risk patients.
Hydroxychloroquine and COVID-19
- We analyze all studies for HCQ and COVID-19. 100% of the 29 early treatment studies report a positive effect (13 statistically significant in isolation) with an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50]. Late treatment is less successful, with only 72% of the 161 studies reporting a positive effect.
- The probability that an ineffective treatment generated results as positive as the 238 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000016).
- 92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.
- There is evidence of bias towards publishing negative results. 88% of prospective studies report positive effects, and only 73% of retrospective studies do.
- Studies from North America are 3.7 times more likely to report negative results than studies from the rest of the world combined, p = 0.0000000020.